Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today extended its ...

Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its isotype-specific secondary antibodies.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), launched four new anti-idiotypic antibodies to the following drugs: atezolizumab (Tecentriq), avelumab (Bavencio), obinutuzumab (Gazyvaro), and ...

HERCULES, Calif., April 21, 2020 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, has extended its range of recombinant ...

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, today extended its range of recombinant monoclonal anti-idiotypic antibodies with the ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of validated antibodies for rare cell and ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of a range of anti-daratumumab antibodies that ...

Bio-Rad Laboratories Inc. (BIO) has started the commercial launch of its blood-based kit test which is used to screen if patients have developed antibodies against SARS-CoV-2, the virus causing ...

Bio-Rad Laboratories recently introduced a range of type 1 antibodies that are designed to inhibit the binding of evolcumab to its target, human proprotein convertase subtilisin/kexin type 9 (PCSK9).

Bio-Rad Laboratories, Inc. BIO announced the launch of a blood-based immunoassay kit to detect antibodies stimulated in the human body in response to the SARS-CoV-2 infection.